A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer

Launched by CELLTRION · Apr 21, 2025

Keywords

ClinConnect Summary

This clinical trial is looking to compare the effects and safety of a new treatment called CT-P51 with an approved treatment known as Keytruda for patients who have not yet received treatment for advanced non-squamous non-small cell lung cancer (nsNSCLC). Both treatments will be given alongside a combination of chemotherapy drugs. The goal is to find out which option works better and is safer for patients with this type of lung cancer.

To be eligible for this trial, participants must be diagnosed with stage IV non-squamous NSCLC and have not previously received treatment for their cancer. They also need to have at least one tumor that can be measured. The trial is open to both men and women aged 65 to 74. If you join this study, you will receive either CT-P51 or Keytruda along with chemotherapy, and you will be closely monitored by the medical team to track your health and any side effects. It’s important to know that individuals with certain types of lung cancer or specific allergies to the study drugs cannot participate in this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Stage IV, non squamous NSCLC
• • Have not received any prior systemic anti-cancer therapy for metastatic NSCLC
• • Have at least 1 measurable lesion per RECIST version 1.1
• Exclusion Criteria:
• • Have predominantly squamous cell histology NSCLC.
• • Hypersensitivity or contraindication to any component of the study drug, pemetrexed and cisplatin or carboplatin